As CMS moves to value-based payments, having good measures of value that payers and providers trust will be critical, explained Stuart Guterman, senior scholar in residence AcademyHealth.
As CMS moves to value-based payments, having good measures of value that payers and providers trust will be critical, explained Stuart Guterman, senior scholar in residence AcademyHealth.
Transcript (slightly modified for readability)
What is the biggest challenge of CMS' timeline of moving Medicare to value-based payments?
The big challenge is going to be to do it and to be able to come up with measures—if you're talking about value-based purchasing, then you need to have good measures of value. Although we've come a really long way in measuring the quality of care received by Medicare beneficiaries and other patients, we still have a long way to go. We're still in the adolescence of that process. So it's a challenge when you're talking about moving a lot of payment to a value basis if you don't have complete confidence in your measures of value. And that's going to have to be worked out.
I actually worked at CMS previously and we had to confront that kind of thing and we realized that until you start putting money that matters onto a set of measures, you're not going to be able to improve those measures the way you would if you could start realizing that payment is based on that.
I think there's a lot of work to be done: I think that's the challenge. And I think there has to be really good cooperation between the public and private payers and the providers to come up with measure that everybody trusts.
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
Specialty Drug Costs Drive Medicare Part D Dermatology Expenditures
July 22nd 2025The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.
Read More